Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the stan...
HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 horm...
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments ...
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved...
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternativ...
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...
TANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-meta...
In Japan, two Phase 3 clinical studies are underway. STARLIGHT 2 is evaluating the efficacy and safety of fezolinetant once-dai...
